Risk Factor Analysis of Anaphylactic Reactions in Patients With Systemic Mastocytosis
- PMID: 28351784
- DOI: 10.1016/j.jaip.2017.02.008
Risk Factor Analysis of Anaphylactic Reactions in Patients With Systemic Mastocytosis
Abstract
Background: Systemic mastocytosis (SM) is a rare disorder of abnormal mast cells in at least 1 extracutaneous organ/tissue. Anaphylaxis is an acute, severe systemic hypersensitivity reaction, and a strong association between SM and anaphylaxis has been shown. However, not all patients with SM experience anaphylaxis. Presently, there are no predictive markers to discriminate patients with SM at high risk of anaphylaxis from those at low risk.
Objective: This study sought to determine risk factors for the occurrence of anaphylaxis in patients with SM.
Methods: A cross-sectional study was conducted in 122 consecutive adult patients with SM admitted to the Mastocytosis Center at Karolinska University Hospital. All patients underwent medical evaluation, including bone marrow biopsy and a thorough allergy workup. To determine risk factors, study subjects were categorized into 2 groups according to the presence (n = 55) or absence (n = 67) of anaphylaxis and compared for their demographic, clinical, and biochemical characteristics.
Results: Patients with SM with anaphylaxis had less frequent presence of mastocytosis in the skin (P < .001), more atopic predisposition (P = .021), higher total IgE levels (P < .001), and lower baseline tryptase levels (27 ng/mL vs 42 ng/mL; P = .024) compared with patients with SM without anaphylaxis.
Conclusions: Patients with SM with anaphylaxis display unique clinical and laboratory features. Hence, a risk analysis tool that is capable of discriminating patients with SM at high risk of anaphylaxis from those at low risk with 86% sensitivity was developed by using the variables male sex, absence of mastocytosis in the skin, presence of atopy, IgE levels of 15 kU/L or more, and baseline tryptase levels of less than 40 ng/mL.
Keywords: Anaphylaxis; Atopy; IgE; Mastocytosis; Risk assessment tool; Risk factors; Tryptase; Venom.
Copyright © 2017 American Academy of Allergy, Asthma & Immunology. All rights reserved.
Similar articles
-
High prevalence of anaphylaxis in patients with systemic mastocytosis - a single-centre experience.Clin Exp Allergy. 2014 Jan;44(1):121-9. doi: 10.1111/cea.12225. Clin Exp Allergy. 2014. PMID: 24164252
-
Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM.J Allergy Clin Immunol. 2014 Feb;133(2):520-8. doi: 10.1016/j.jaci.2013.06.020. Epub 2013 Aug 6. J Allergy Clin Immunol. 2014. PMID: 23921094
-
Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis.Immunotherapy. 2011 May;3(5):637-51. doi: 10.2217/imt.11.44. Immunotherapy. 2011. PMID: 21554093 Review.
-
Fatal Anaphylaxis to Yellow Jacket Stings in Mastocytosis: Options for Identification and Treatment of At-Risk Patients.J Allergy Clin Immunol Pract. 2017 Sep-Oct;5(5):1264-1271. doi: 10.1016/j.jaip.2017.03.019. Epub 2017 May 10. J Allergy Clin Immunol Pract. 2017. PMID: 28499778
-
[Tryptase: A practical guide for the physician].Rev Med Interne. 2020 Nov;41(11):748-755. doi: 10.1016/j.revmed.2020.06.006. Epub 2020 Jul 23. Rev Med Interne. 2020. PMID: 32712042 Review. French.
Cited by
-
Diagnostic Significance of Tryptase for Suspected Mast Cell Disorders.Diagnostics (Basel). 2023 Dec 14;13(24):3662. doi: 10.3390/diagnostics13243662. Diagnostics (Basel). 2023. PMID: 38132246 Free PMC article. Review.
-
A Puzzling Mast Cell Trilogy: Anaphylaxis, MCAS, and Mastocytosis.Diagnostics (Basel). 2023 Oct 25;13(21):3307. doi: 10.3390/diagnostics13213307. Diagnostics (Basel). 2023. PMID: 37958203 Free PMC article. Review.
-
Diagnostic Evaluation of Hypersensitivity Reactions to Antibiotics in a Large Cohort of Mastocytosis Patients.Diagnostics (Basel). 2023 Jun 30;13(13):2241. doi: 10.3390/diagnostics13132241. Diagnostics (Basel). 2023. PMID: 37443635 Free PMC article.
-
Assessment of low immunoglobulin levels and clinical manifestations in patients with mastocytosis.J Allergy Clin Immunol Glob. 2023 Feb;2(1):105-110. doi: 10.1016/j.jacig.2022.08.005. Epub 2022 Oct 4. J Allergy Clin Immunol Glob. 2023. PMID: 36873731 Free PMC article.
-
Comprehensive mastocytosis data analysis from a single center.BMC Cancer. 2023 Jan 24;23(1):82. doi: 10.1186/s12885-022-10498-3. BMC Cancer. 2023. PMID: 36694141 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
